Dr. Choi-Fong Cho of Harvard Medical School spoke to CHI to discuss her breakthrough research and the development of BBB organoids to be used as a next-generation screening model for brain-penetrating molecules. She discusses next steps in her research, including investigating new compounds and drugs with this platform, as well as the potential to unlock new mechanisms and pathways.

Dr. Cho is speaking at the Blood-Brain Barrier conference, part of World Preclinical Congress, taking place June 18-21, 2018 in Boston, MA. For more details, please visit: http://www.worldpreclinicalcongress.com

Dr. Andrew Bradbury talks about his latest work using NGS to build a single donor library, and shares lessons he has learned along the way. He describes the unique approach they are using at Specifica and outlines tips for creating antibody libraries with improved diversity and developability.

For more information, please visit http://www.PEGSummit.com/Phage-Display/

Dr. Andreas Stange of TÜV SÜD talks about the practical impact of the new IVD regulation, how it will affect manufacturers and notified bodies, challenges in validation, and practical advice to prepare for these changes in companion diagnostics.

For more information, please visit http://www.MolecularDXEurope.com/MDXE_Content.aspx?id=190671

Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward.

For more information please visit http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/

Dr. Jorg Tost recently spoke to CHI to discuss his work with the ice-COLD-PCR assay and how it is addressing current challenges in cfDNA analysis. He also discusses challenges related to data, new technologies, and including other biomarkers in addition to cfDNA for the most complete and accurate analysis. Dr. Tost is speaking at the Enabling Technologies for Cell-Free DNA Analysis conference, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal.

For more information, please visit http://www.MolecularDXEurope.com/Cell-Free-DNA-Technology/

As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a study within 24 hours -- all of these scenarios are possible in the digital era of medicine. In this podcast, we will explore new methods for:

· Integrating data from wearables, sensors, and apps into a study and constructing better measures of individual health

· Developing novel endpoints based on an individual’s day-to-day experience

· Leveraging big data and AI to predict disease onset, progression/regression, acute events, and identify key intervention points

· Optimizing study recruitment and protocol compliance through digital channels

For more information, please visit http://www.Bio-ITWorld.com

Podcast uploaded for approval.

Cambridge Healthtech Institute’s Kent Simmons recently spoke with Dr. David Johnson, CEO of GigaGen, about his upcoming presentation “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods”, to be delivered in the Engineering Antibodies meeting at the 2018 PEGS Boston. PEGS is scheduled for April 30 - May 4, 2018 in Boston, with the antibodies program set for May 2-3.

For more information, please visit http://www.PEGSummit.com/Engineering-Antibodies

Patrizia Paterlini-Brechot spoke to CHI to discuss her work in cell-based non-invasive prenatal diagnosis and some of the challenges in commercializing this technique. She also discusses the impact commercialized NIPD tests will have on the field of prenatal diagnosis and some of the new frontiers she expects will be next. Dr. Paterlini-Brechot is speaking at the Advances in prenatal Molecular Diagnostics meeting, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal

For more information, please visit http://www.MolecularDXEurope.com/Prenatal-Dx/

Dr. David Barton summarizes the new EU IVD regulations and highlights their key features. He will explain what the ramifications of introducing these new regulations for labs and manufacturers will be and advice for people preparing for the change.

For more information, please visit http://www.MolecularDXEurope.com/mdxe_content.aspx?id=190671